Intensity Therapeutics, Inc. (INTS)
| Market Cap | 52.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.86M |
| Shares Out | 13.71M |
| EPS (ttm) | -1.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,165 |
| Open | 4.050 |
| Previous Close | 3.940 |
| Day's Range | 3.810 - 4.120 |
| 52-Week Range | 2.010 - 11.440 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.00 (+214.96%) |
| Earnings Date | May 6, 2024 |
About INTS
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for INTS stock is "Buy" and the 12-month stock price forecast is $12.0.
News
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
SHELTON, Conn. , April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer Year-end cash and investments of $14.8 million expected to fund operations through th...
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
SHELTON, Conn. , March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel ...
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
SHELTON, Conn. , Feb. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
FDA provides "Study May Proceed" letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn. , Jan. 3, 2024 /PRN...
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn...
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single inject...
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
WESTPORT, Conn. , Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune...
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society ("CTOS"), demonstrating 93% disease control rate in patien...
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
The disease control rate for subjects in the monotherapy was 93% for patients who received at least one dose of INT230-6 INT230-6 extended survival in refractory soft tissue sarcoma subjects by nearly...
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
WESTPORT, Conn. , Sept. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and developm...
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WESTPORT, Conn. , Sept. 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immun...
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented at ASCO Showed that Lead Asset INT230-6 Prolongs Survival Alone or in Combi...
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology compa...
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
WESTPORT, Conn. , July 10, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and developm...
Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
WESTPORT, Conn. , July 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and developme...
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
WESTPORT, Conn. , June 29, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and developm...
Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
INT230-6 Induced T-Cell Receptor Signaling, Macrophage Markers, and IL-18 and B-Cell Receptor Signaling Data Was Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Ju...
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment L...
Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)
Study accepted for a Spotlight Session Poster Presentation WESTPORT, Conn. , Dec. 8, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused o...
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO
Data from Ongoing Phase 1/2 Study of INT230-6 Alone or in Combination with Ipilimumab (INTENSITY# IT-01; BMS# CA184-592) Selected for Oral Podium Presentation Exploratory Kaplan Meier Analysis of the ...
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a V...
Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers
Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single Injection of up to 100% of a Tumor was Observ...